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   Preface 
The first chapter “An Adaptive Fisher’s Combination Method for Joint Analysis of 
Multiple Phenotypes in Association Studies” was published in Scientific Reports in 
October 2016. The second chapter “Joint Analysis of Multiple Phenotypes in Association 
Studies Using Allele-based Clustering Approach for Non-Normal Distributions” was 
invited for revision and the revision is under the review in Annals of Human Genetics. 
The third chapter “A Hierarchical Clustering Method for Dimension Reduction in Joint 
Analysis of Multiple Phenotypes” was accepted by Genetic Epidemiology in February 
2018. For all three chapters, Dr. Shuanglin Zhang and Dr. Qiuying Sha designed 
researches, Dr. Shuanglin Zhang and Xiaoyu Liang performed statistical analyses, Dr. 
Shuanglin Zhang, Dr. Qiuying Sha, and Xiaoyu Liang wrote the manuscripts. In the first 
chapter, Zhenchuan Wang performed real data analysis. In the third chapter, Dr. 
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   Abstract 
Genome-wide association studies (GWAS) have become a very effective research tool to 
identify genetic variants of underlying various complex diseases. In spite of the success 
of GWAS in identifying thousands of reproducible associations between genetic variants 
and complex disease, in general, the association between genetic variants and a single 
phenotype is usually weak. It is increasingly recognized that joint analysis of multiple 
phenotypes can be potentially more powerful than the univariate analysis, and can shed 
new light on underlying biological mechanisms of complex diseases. Therefore, 
developing statistical methods to test for genetic association with multiple phenotypes 
has become increasingly important. This dissertation contains three chapters and the three 
chapters include three new methods we developed for jointly analyzing multiple 
phenotypes.  
In the first chapter of this dissertation, we propose an Adaptive Fisher’s 
Combination (AFC) method for joint analysis of multiple phenotypes in association 
studies. The AFC method combines p-values obtained in standard univariate GWAS by 
using the optimal number of p-values which is determined by the data. In the second 
chapter, we propose an Allele-Based Clustering (ABC) approach for the joint analysis of 
multiple non-normal phenotypes in association studies. In the ABC method, we consider 
the alleles at a SNP of interest as a dependent variable with two classes, and the 
correlated phenotypes as predictors to predict the alleles at the SNP of interest. In the 
third chapter, we develop a novel variable reduction method using hierarchical clustering 
method (HCM) for joint analysis of multiple phenotypes in association studies. HCM 
involves two steps. The first step applies a dimension reduction technique by using a 
representative phenotype for each cluster of phenotypes. Then, existing methods are used 
in the second step to test the association between genetic variants and the representative 
phenotypes rather than the individual phenotypes. We perform extensive simulations to 




methods with the powers of some existing methods. Our simulation studies show that the 
proposed methods have correct type I error rates and are either the most powerful test or 
comparable with the most powerful test. Finally, we illustrate our proposed 
methodologies AFC and HCM by analyzing whole-genome genotyping data from a lung 
function study. The results of real data analysis demonstrated that the proposed methods 
have great potential in GWAS on complex diseases with multiple phenotypes.  
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1   An Adaptive Fisher’s Combination Method for Joint 
Analysis of Multiple Phenotypes in Association Studies 
Currently, the analyses of most genome-wide association studies (GWAS) have been 
performed on a single phenotype. There is increasing evidence showing that pleiotropy is 
a widespread phenomenon in complex diseases. Therefore, using only one single 
phenotype may lose statistical power to identify the underlying genetic mechanism. There 
is an increasing need to develop and apply powerful statistical tests to detect association 
between multiple phenotypes and a genetic variant. In this study, we develop an Adaptive 
Fisher’s Combination (AFC) method for joint analysis of multiple phenotypes in 
association studies. The AFC method combines p-values obtained in standard univariate 
GWAS by using the optimal number of p-values which is determined by the data. We 
perform extensive simulations to evaluate the performance of the AFC method and 
compare the power of our method with the powers of TATES, Tippett’s method, Fisher’s 
combination test, MANOVA, MultiPhen, and SUMSCORE. Our simulation studies show 
that the proposed method has correct type I error rates and is either the most powerful test 
or comparable with the most powerful test. Finally, we illustrate our proposed 
methodology by analyzing whole-genome genotyping data from a lung function study.  
 
1.1   Background 
To date, genome-wide association studies (GWAS) have become a tool of choice for the 
identification of genetic variants associated with complex human diseases. Currently, the 
analyses of most GWAS have been performed on a single phenotype. There is increasing 
evidence showing that pleiotropy, the effect of one variant on multiple phenotypes, is a 
widespread phenomenon in complex diseases (Sivakumaran et al., 2011; Wang et al., 
2016b). Therefore, using only one single phenotype may lose statistical power to identify 
the underlying genetic mechanism. By taking into account the correlated structure of 
multiple phenotypes, we can not only discover genetic variants influencing multiple 
phenotypes that may lead to better understanding of etiology of complex human diseases 
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(He et al., 2013; Wang, 2014), but also can improve the statistical power by aggregating 
multiple weak effects and provide new biological insights by revealing pleiotropic 
variants (Amos & Laing, 1993; Jiang & Zeng, 1995; Schifano et al., 2013). 
Consequently, there is an increasing need to develop powerful statistical methods to 
detect association between multiple phenotypes and genetic variants.  
Recently, several statistical methods for detecting association using multivariate 
phenotypes have been developed (Klei et al., 2008; Li et al., 2011; O’Reilly et al., 2012; 
Tang & Ferreira, 2012; van der Sluis et al., 2013; Yan et al., 2013). These methods can 
be divided into three groups: regression models, variable reduction method, and 
combining test statistics from univariate analysis (Yang & Wang, 2012). Regression 
models, such as linear mixed effects models, generalized mixed effects models, and 
generalized estimating equations, can be used to test the association between a genetic 
variant and multiple phenotypes. By using random effects to account for correlation 
among individuals, linear and generalized mixed effect models can model the covariance 
structure not only caused by correlated phenotypes, but also caused by population 
structure (Bates & DebRoy, 2004; Breslow & Clayton, 1993; Fitzmaurice & Laird, 1993; 
Laird & Ware, 1982; Yan et al., 2013). Generalized estimating equations collapse random 
effects and random residual errors in the model (Liang & Zeger, 1986). Existing variable 
reduction methods can be roughly divided into three categories, principal components 
analysis of phenotypes (PCP) (Aschard et al., 2014), canonical correlation analysis 
(CCA) (Tang & Ferreira 2012) and principal component of heritability (PCH) (Klei et al., 
2008; Ott & Rabinowitz, 1999). The PCP approach applies a dimension reduction 
technique and tests for associations between genetic variants and the principle 
components of the phenotypes rather than the individual phenotypes. CCA provides a 
convenient statistical framework to simultaneously test the association between any 
number of quantitative phenotypes and any number of genetic variants genotyped across 
a gene or region of interest for unrelated individuals. For each genetic variant, the PCH 
approach reduces the phenotypes to a linear combination of phenotypes that has the 
highest heritability among all linear combinations of the phenotypes. Based on PCH, 
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several advanced methods have been proposed such as penalized PCH applicable to high-
dimensional data (Wang et al., 2007a; Wang et al., 2007b) and principle components of 
heritability with coefficients maximizing the quantitative phenotype locus heritability 
(PCQH) (Ferreira & Purcell, 2009; Klei et al., 2008; Lange et al., 2002). The third group, 
combining test statistics from univariate tests, is to conduct univariate analysis on each 
phenotype, then combine the univariate test statistics (Yang et al., 2010). The Trait-based 
Association Test that uses Extended Simes procedure (TATES) (van der Sluis et al., 
2013) belongs to this group. TATES combines p-values obtained in standard univariate 
GWAS while correcting for the correlation between p-values. 
Motivated by TATES, in this article, we propose an Adaptive Fisher’s 
Combination (AFC) method for joint analysis of multiple phenotypes in genetic 
association studies. We first test the association between each of the phenotypes and a 
genetic variant of interest using standard GWAS software. Then, AFC uses the optimal 
number of p-values which is determined by the data to test the association. Using 
extensive simulation studies, we evaluate the performance of the proposed method and 
compare the power of the proposed method with the powers of TATES, Tippett’s method 
(Pesarin & Salmaso, 2010), Fisher’s Combination test (FC) (Yang et al., 2016), 
Multivariate Analysis of Variance (MANOVA) (Cole et al., 1994), joint model of 
Multiple Phenotypes (MultiPhen) (O’Reilly et al., 2012), and Sum Score method 
(SUMSCORE) (van der Sluis et al., 2013). Our simulation studies show that the proposed 
method has correct type I error rates and is either the most powerful test or comparable 
with the most powerful tests. Finally, we illustrate our proposed methodology by 




1.2   Methods 
1.2.1   Adaptive Fisher’s Combination Method  
Consider a sample of 𝑛 unrelated individuals. Each individual has 𝐾 phenotypes. Denote 
𝑌$ = (𝑦($,… , 𝑦+$)- as the 𝑘/0 phenotype of 𝑛 individuals. Denote 𝑋 = (𝑥(,… , 𝑥+)- as 
the genotypic score of 𝑛 individuals at a genetic variant of interest, where 𝑥3 ∈ {0, 1, 2} is 
the number of minor alleles that the 𝑖/0 individual carries at the genetic variant. We 
propose a new method to test the null hypothesis 𝐻<: none of the 𝐾 phenotypes are 
associated with the genetic variant.  
We test the association between each phenotypic vector 𝑌$ (𝑘 = 1, 2, … ,𝐾) and 
the genotypic score 𝑋 using a standard GWAS software (e.g. PLINK, Gen/ProbABEL, 
MaCH, SNPTEST, and FaST-LMM) (Aulchenko et al., 2007; Aulchenko et al., 2010; Li 
et al., 2009; Li et al., 2010; Lippert et al., 2011; Marchini et al., 2007; Purcell et al., 
2007). Let 	  𝑝(,𝑝?,…,𝑝@  denote the p-values obtained by the standard univariate GWAS. 
Based on these p-values, we propose an Adaptive Fisher’s Combination (AFC) method to 
test the association between multiple phenotypes and the genetic variant. Let 𝑝($) denote 
the 𝑘/0 smallest p-value, 𝑇$ = −∑ Dlog𝑝(3)H$3I( (	  𝑘 = 1, 2,… , 𝐾), and 𝑝-J  denote the p-
value of 𝑇$	  . The statistic of AFC to test the association between the 𝐾 phenotypes and 
the genetic variant is given by 𝑇KLL = min(P$P@ 𝑝-J . We use the following permutation 
procedure to evaluate the p-values of	  	  𝑇$  and	  	  𝑇KLL. 
1.   In each permutation, we randomly shuffle the genotypes and recalculate 
𝑝((), … , 𝑝(@) and 𝑇(,… , 𝑇@. Suppose that we perform 𝐵 times of permutations. Let 
𝑇$
(T) (𝑏 = 0,1, … , 𝐵) denote the value of 𝑇$ based on the 𝑏/0  permuted data, 
where 𝑏 = 0 represents the original data.  
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As shown in Appendix, the null distributions of 𝑝(,𝑝?,…,𝑝@  and thus of 𝑇KLL do not 
depend on the genetic variant being tested. Thus, the permutation procedure described 
above to generate an empirical null distribution of 𝑇KLL needs to be done only once for a 
GWAS. 
The R code of AFC is available at Shuanglin Zhang’s homepage 
http://www.math.mtu.edu/~shuzhang/software.html. 
 
1.2.2   Comparison of Methods 
We compare the performance of our method with those of TATES (van der Sluis et al., 
2013), Tippett’s method (Pesarin & Salmaso, 2010), Fisher’s Combination test (FC) 
(Yang et al., 2016), Multivariate Analysis of Variance (MANOVA) (Cole et al., 1994), 
joint model of Multiple Phenotypes (MultiPhen) (O’Reilly et al., 2012), and Sum Score 
method (SUMSCORE) (van der Sluis et al., 2013). Here we briefly introduce each of 
those methods using the notations in the method section. 
TATES: Combine the 𝐾 phenotype-specific p-values obtained in standard 




i, where 𝑚k denotes the 
effective number of independent p-values of all 𝐾 phenotypes, and 𝑚k($) denotes the 
effective number of p-values among the top 𝑘 p-values. 
MANOVA: Consider a multivariate multiple linear regression model: 𝒀 =
𝑋𝛽- + 𝓔, where 𝒀 denotes the 𝑛 × 𝐾 matrix of phenotypes, 𝛽- = (𝛽(, … , 𝛽@) is a vector 
of coefficients corresponding to the 𝐾 phenotypes, and 𝓔 is the 𝑛 × 𝐾 matrix of random 
errors with each row of 𝓔 to be i.i.d. 𝑀𝑉𝑁(0, 𝚺), where 𝚺 is the covariance matrix of 𝓔. 
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To test 𝐻<: 𝛽 = 0, the likelihood ratio test is equivalent to the Wilk’s Lambda test 




= −𝑛 logv |𝑬||𝑬}𝑯|z. Here Λ denote the ratio of the likelihood function under 𝐻< to 
the likelihood function under 𝐻(, 𝑙(𝛽, 𝜮) is the log-likelihood function,  𝑯 = 𝛽x(𝑋-𝑋)𝛽x- 
and 𝑬 = 𝒀-𝒀 − 𝛽x(𝑋-𝑋)𝛽x-, where 𝛽x = 𝒀-𝑋(𝑋-𝑋)( is the maximum likelihood 
estimator (MLE) of 𝛽, and |∙| denotes the determinant of a matrix. Then the test statistic 
has an asymptotic 𝜒@?  distribution (Ray et al., 2016). 
MultiPhen: By performing ordinal regression, MultiPhen develops a reversed 
analysis for joint analysis of multiple phenotypes by considering a genetic variant of 
interest 𝑋 = (𝑥(,… , 𝑥+)- as a response variable, and the correlated phenotypes 𝑌$ =
(𝑦($, … , 𝑦+$)- as predictors. 
SUMSCORE: Let 𝑇]^k$  denote the score test statistic to test the association 
between the 𝑘/0 phenotype and the genetic variant. The test statistic of SUMSCORE is 
given by 𝑇 = ∑ 𝑇]^k$@$I( . The p-value of 𝑇  is estimated using a 
permutation procedure.  
Tippett: The test statistic of Tippett is given by 𝑇-3hhk// = min$ 𝑝$ . The p-value 
of 𝑇-3hhk// is estimated using a permutation procedure.  
FC: The Fisher’s combination test statistic is defined as 𝑇 = ∑ −2 log(𝑝$)@$I( . 
Yang et al. (Yang et al., 2016) adopted three different approaches to calculate the p-value 
for correlated phenotypes. In this article, we calculate the p-value using a permutation 
procedure. 
AFC, FC, and Tippett are closely related. Intuitively, when only one phenotype or 
very few phenotypes are associated with the variant, Tippett is more powerful than FC 
because in this case FC contains a lot of noises. When all phenotypes or a large 
proportion of the phenotypes are associated with the variant, FC is more powerful than 
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Tippett because in this case Tippett only uses the minimum p-value and loses 
information. AFC can be adaptive to the number of phenotypes associated with the 
variant.   
 
1.3   Results 
1.3.1   Simulation Studies  
We generate genotype data at a genetic variant according to a minor allele frequency 
(MAF) under Hardy-Weinberg equilibrium. Phenotypes are generated similarly to that of 
van der Sluis et al. (van der Sluis et al., 2013). The phenotypic correlation structures 
mimic that of UK10K (UK10K Consortium, 2015), that is, the phenotypes are divided 
into several groups (factors) and the within-group correlation is larger than the between-
group correlation. Denote 𝑌$ = (𝑦($, … , 𝑦+$)- as the 𝑘/0 phenotype of 𝑛 individuals and 
𝑋 = (𝑥(, … , 𝑥+)- as the genotypic score of the 𝑛 individuals at the genetic variant.  
Scenario 1: considering one factor model with genetic variant effect on the 
factor. We first generate a common factor, 𝑓 = 𝛽𝑋, where 𝑓 is the 𝑛 by 1 common factor 
and 𝛽 is the effect size. Then we simulate 𝐾 phenotypes by  
𝑌$ = 𝑎𝑓 + 𝜀$ for 𝑘 = 1,2,… , 𝐾,                                         (3) 
where 𝑎 is a factor loading, 𝜀$ = (𝜀($,… , 𝜀+$)𝑻~𝑀𝑉𝑁(0, 𝑰𝒏), and 𝑰𝒏 is the identity 
matrix. 
Scenario 2: considering 4 factor model with the genetic variant effect on the 
fourth factor, each factor has @

 (𝐾 is a multiple of 4) phenotypes. We generate 4 
correlated factors using (𝑓(, 𝑓?, 𝑓, 𝑓)-~𝑀𝑉𝑁(0, 𝚺), where 𝚺 = D1 − 𝜌\KH𝑰 + 𝜌\K𝑨, 𝑨 is 
a matrix with elements of 1, 𝑰 is the identity matrix, and 𝜌\K  is the correlation between 
any two factors. Then, we transform the fourth factor 𝑓 to 𝑓∗	  by 𝑓∗ = 𝑓 + 𝛽𝑋 and 








⎧𝑎𝑓( + 𝜀(	  𝑓𝑜𝑟	  𝑘 = 1,… ,
@

	  	  	  	  	  	  	  	  	  	  	  	  
𝑎𝑓? + 𝜀?	  𝑓𝑜𝑟	  𝑘 =
@

+ 1,… , @
?
	  	  	  
𝑎𝑓 + 𝜀	  𝑓𝑜𝑟	  𝑘 =
@
?
+ 1,… , @

𝑎𝑓∗ + 𝜀	  𝑓𝑜𝑟	  𝑘 =
@

+ 1, … ,𝐾
                                             (4) 
where 𝑎 is a factor loading,	  𝜀  = D𝜀( ,… , 𝜀+ H
-
~	  𝑀𝑉𝑁(0, 𝑰𝒏) for 𝑗 = 1,… ,4, and 𝛽 is the 
effect size.  
Scenario 3: considering two factor model with the genetic variant effect on the 
second factor, each factor has @
?
 (𝐾 is a multiple of 2) phenotypes. We generate two 
correlated factors using (𝑓(, 𝑓?)-~𝑀𝑉𝑁(0, 𝚺), where 𝚺 = D1 − 𝜌\KH𝑰 + 𝜌\K𝑨, 𝑨 is a 
matrix with elements of 1, 𝑰 is the identity matrix, and 𝜌\K  is the correlation between any 
two factors. Then, we transform the second factor 𝑓? to 𝑓?∗	  by 𝑓?∗ = 𝑓? + 𝛽𝑋 and simulate 
𝐾 phenotypes using  
𝑌$ = £
𝑎𝑓( + 𝜀(	  𝑓𝑜𝑟	  𝑘 = 1, … ,
@
?




                                          (5) 
where 𝑎 is a factor loading,	  𝜀  = D𝜀( ,… , 𝜀+ H
-
~	  𝑀𝑉𝑁(0, 𝑰𝒏) for 𝑗 = 1,2, and 𝛽 is the 
effect size. 
Scenario 4: considering 4 factor model with genetic variant effect specific to the 
𝐾/0 phenotype, each factor has @

 (𝐾 is a multiple of 4) phenotypes. By using the original 








⎧ 𝑎𝑓( + 𝜀(	  𝑓𝑜𝑟	  𝑘 = 1,… ,
@

	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
𝑎𝑓? + 𝜀?	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where 𝑎 is a factor loading,	  𝜀  = D𝜀( ,… , 𝜀+ H
-
~𝑀𝑉𝑁(0, 𝑰𝒏) for 𝑗 = 1,… ,4, and 𝛽 is the 
effect size.   
Scenario 5: considering one factor model with the genetic variant effect specific 
to the 𝐾/0 phenotype. We simulate 𝐾 phenotypes by  
𝑌$ = ¤
𝑎𝑓 + 𝜀$	  𝑓𝑜𝑟	  𝑘 = 1, … ,𝐾 − 1
𝑎(𝑓 + 𝛽𝑋)+𝜀$	  𝑓𝑜𝑟	  𝑘 = 𝐾	  	  	  	  	  	  	  
                               (7) 
where 𝑓~	  𝑀𝑉𝑁(0, 𝑰𝒏), 𝑎 is a factor loading, 𝜀$ = (𝜀($,… , 𝜀+$)𝑻~𝑀𝑉𝑁(0, 𝑰𝒏), and 𝑰𝒏 is 
the identity matrix, and 𝛽 is the effect size  
Scenario 6: considering a network model, where the 𝐾 phenotypes are correlated 
and the correlation structure is not due to one or multiple underlying common factors. We 
generate 𝐾 phenotypes independent of genotypes for each individual by using 
D𝑌¥(,… , 𝑌¥@H
-
~𝑀𝑉𝑁(0, 𝚺), where 𝚺 = D1 − 𝜌h0kH𝑰 + 𝜌h0k𝑨, 𝑨 is a matrix with elements 
of 1, 𝑰 is the identity matrix, and 𝜌h0k  is the correlation between any two phenotypes. 
After generating	  𝑌¥(, … , 𝑌¥@	  , let 𝑌$ = 𝛽𝑋 + 𝑌¥$ + 𝜀$, where 𝜀$ =
(𝜀($,… , 𝜀+$)-~𝑀𝑉𝑁(0, 𝑰𝒏). 
In scenarios 2-5, the within-factor correlation is 𝑎? and between-factor correlaiton 
is 𝑎?𝜌\K . To evaluate type I error of the proposed method, we generate phenotypic values 
independent of genotypes by assigning  𝛽 = 0. To evaluate power, we generate 




1.3.2   Simulation Results  
We use two sets of simulations to evaluate the type I error rates of the proposed method. 
The first set of simulations is normal simulation studies and includes 10,000 replicated 
samples for each sample size under each scenario. The p-values are estimated using 
10,000 permutations. For 10,000 replicated samples, the 95% confidence intervals (CIs) 
for type I error rates at the nominal levels 0.01 and 0.001 are (0.008, 0.012) and (0.0004, 
0.0016), respectively. The estimated type I error rates of the proposed test (AFC) are 
summarized in Table 1.1. From Table 1.1, we can see that most of the estimated type I 
error rates are within the 95% CIs and those type I error rates not within the 95% CIs are 
very close to the bound of the corresponding 95% CI, which indicates that the proposed 
method is valid. 
The second set of simulations mimics GWAS. To be comparable with the real 
data analysis, we generate 6,000 unrelated individuals with 8 phenotypes at  variant 
sites under each scenario. The phenotypes are independent of genotypes. The MAF at 
each variant is a random number between 0.05 and 0.5. The null distributions of  
and 𝑇KLL are generated by  permutations using the genotypes at the first variant. We 
consider genotypes at  variants as  replicated samples. For  replicated 
samples, the 95% confidence intervals (CIs) for the type I error rates at the nominal levels 
, , and  are (0.94 × 10, 1.06 × 10), (0.8 × 10, 1.20 × 10), and 
(0.38 × 10«, 1.62 × 10«), respectively. The estimated type I error rates of the 
proposed test (AFC) are summarized in Table 1.2. From Table 1.2, we can see that all of 
the estimated type I error rates are within the 95% CIs, which indicates that the proposed 
method is valid. 
For power comparisons, we consider (1) power as a function of the effect size 
under all six scenarios, and (2) power as a function of factorial correlation (𝜌\K)	  under 
scenarios 2-4 and power as a function of phenotypic correlation (𝜌h0k) under scenario 6 
because scenarios 1 and 5 are one factor model and thus have no 𝜌\K  and 𝜌h0k  involved. 
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For Figures 1.1 and 1.2, the p-values of AFC, FC, Tippett, and SUMSCORE are 
estimated using 10,000 permutations and the p-values of TATES, MultiPhen, and 
MANOVA are estimated using asymptotic distributions. The powers of all tests are 
evaluated using 1,000 replicated samples at 0.1% significance level. For Figure 1.3, the 
p-values of AFC, FC, Tippett, and SUMSCORE are estimated using 107 permutations. 
The powers of all tests are evaluated using 1,000 replicated samples at 10-6 significance 
level. 
Figure 1.1 gives the power comparisons of the 7 tests (AFC, TATES, Tippett, FC, 
MANOVA, MultiPhen, and SUMSCORE) for the power as a function of the effect size 
based on the six scenarios for 20 phenotypes. This figure shows that (1) AFC is either the 
most powerful test (genotypes directly impact on a portion of the phenotypes: scenarios 
2-3) or comparable to the most powerful test (genotypes directly impact on all 
phenotypes or a single phenotype: scenarios 1, 4, 5, and 6); (2) TATES and Tippett have 
similar power and are much less powerful than other methods when genotypes directly 
impact on all phenotypes (scenarios 1 and 6); (3) MANOVA and MultiPhen have similar 
power and are much less powerful than other methods when genotypes directly impact on 
a portion of the phenotypes (scenarios 2-3); and (4) SUMSCORE and FC have similar 
power and are much less powerful than other methods when genotypes directly impact on 
a single phenotype (scenarios 4-5).  
Power comparisons of the 7 tests for the power as a function of the factorial 
correlation ( 𝜌\K) under scenarios 2-4 and as a function of the phenotypic correlation 
(𝜌h0k) under scenario 6 are given by Figure 1.2. This figure shows that under scenario 4, 
the powers of all tests do not change with the factorial correlation because only one 
phenotype is associated with the variant and thus the factorial correlation does not change 
the information of association between the variant and phenotypes. Under scenarios 2, 3 
and 6, (1) the powers of SUMSCORE and FC decrease with the increasing of the 
factorial or phenotypic correlation because SUMSCORE and FC involve all phenotypes 
and thus information contained by all phenotypes will decrease with the increasing of the 
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factorial or phenotypic correlation; (2) the powers of TATES and Tippett do not change 
with the increasing of the factorial or phenotypic correlation because TATES and Tippett 
essentially only depend on the phenotype that has the strongest association with the 
variant; (3) under scenario 6, the power of AFC decreases with the increasing of the 
phenotypic correlation; under scenarios 2-3, the power of AFC does not change much 
with the factorial correlation; and (4) under scenario 6, the powers of MANOVA and 
MultiPhen decrease with the increasing of the phenotypic correlation; under scenarios 2-
3, the powers of MANOVA and MultiPhen increase with the increasing of the factorial 
correlation, which is consistent with the results of Ray et al.38. We also give power 
comparisons of the 7 tests using a significance level of 10-6 with 107 permutations and 
1,000 replicates for the power as a function of effect size (β) under scenario 2 (Figure 
1.3). Figure 1.3 shows that the patterns of the power comparisons using significance level 
10-6 are similar to that using a significance level of 0.1% in Figure 1.1 (scenario 2). 
In summary, the proposed method has correct type I error rates and is either the 
most powerful test or comparable with the most powerful tests. No other methods have 
consistently good performance under the six simulation scenarios. 
 
1.3.3   Real Data Analysis  
Chronic obstructive pulmonary disease (COPD) is one of the most common lung diseases 
characterized by long term poor airflow and is a major public health problem (Nazir & 
Erbland, 2009). The COPDGene Study (Regan et al., 2011) 
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000179.v1.p1) 
is a multi-center genetic and epidemiologic investigation to study COPD. This study is 
sufficiently large and appropriately designed for genome-wide association analysis of 
COPD. In this study, a total of more than 10,000 subjects have been recruited including 
non-Hispanic Whites (NHW) and African-Americans (AA). The participants in this study 
have completed a detailed protocol, including questionnaires, pre- and post-
bronchodilator spirometry, high-resolution CT scanning of the chest, exercise capacity 
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(assessed by six-minute walk distance), and blood samples for genotyping. The 
participants were genotyped using the Illumina OmniExpress platform. The genotype 
data have gone through standard quality-control procedures for genome-wide association 
analysis detailed at 
http://www.copdgene.org/sites/default/files/GWAS_QC_Methodology_20121115.pdf. 
Variants with MAF<1% were excluded in the data set.  
To evaluate the performance of our proposed method on a real data set, we 
applied all of the 7 methods to the COPDGene of NHW population to carry out GWAS 
of COPD-related phenotypes. Based on the literature studies of COPD (Chu et al, 2014; 
Han et al., 2011), we selected 7 key quantitative COPD-related phenotypes, including 
FEV1 (% predicted FEV1), Emphysema (Emph), Emphysema Distribution (EmphDist), 
Gas Trapping (GasTrap), Airway Wall Area (Pi10), Exacerbation frequency 
(ExacerFreq), Six-minute walk distance (6MWD), and 4 covariates, including BMI, Age, 
Pack-Years (PackYear) and Sex. EmphDist is the ratio of emphysema at -950 HU in the 
upper 1/3 of lung fields compared to the lower 1/3 of lung fields. Followed by Chu et al. 
(Chu et al, 2014), we did a log transformation on EmphDist in the following analysis. 
The correlation structure of the 7 COPD-related phenotypes is given in Figure 1.4. In the 
analysis, participants with missing data in any of the 11 variables were excluded. 
Therefore, a complete set of 5,430 individuals across 630,860 SNPs were used in the 
following analyses. In the analysis, we first adjusted each of the 7 phenotypes for the 4 
covariates using linear models. Then, we performed the analysis based on the adjusted 
phenotypes. 
To identify SNPs associated with the phenotypes, we adopted the commonly used 
genome-wide significance level 5 × 10­. The results were summarized in Table 1.3. 
There were total 14 SNPs in Table 1.3. All of the 14 SNPs had previously been reported 
to be in association with COPD by eligible studies (Brehm et al., 2011; Cho et al., 2010; 
Cho et al., 2014; Cui et al., 2014; Du et al., 2016; Hancock et al., 2010; Li et al., 2011b; 
Lutz, et al., 2015; Pillai, et al., 2009; Wilk et al., 2009; Wilk et al., 2012; Young et al., 
2010; Zhang et al., 2011; Zhu et al., 2014). From Table 1.3, we can see that MultiPhen 
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identified 14 SNPs; MANOVA identified 13 SNPs; AFC identified 12 SNPs, FC and 
SUMSCORE identified 10 SNPs; and TATES and Tippett identified 9 SNPs. Among the 
five methods based on combining test statistics from univariate analysis (AFC, TATES, 
Tippett, FC, and SUMSCORE), AFC identified 2 or 3 more genome-wide significant 
SNPs than the other 4 methods.  
 
1.4   Discussion 
GWAS have identified many variants with each variant affecting multiple phenotypes, 
which suggests that pleiotropic effects on human complex phenotypes may be 
widespread. Therefore, statistical methods that can jointly analyze multiple phenotypes in 
GWAS may have advantages over analyzing each phenotype individually. In this article, 
we developed a new method AFC to jointly analyze multivariate phenotypes in genetic 
association studies. We used extensive simulation studies as well as real data application 
to compare the performance of AFC with TATES, Tippett, FC, MANOVA, MultiPhen, 
and SUMSCORE. Our simulation results showed that AFC has correct type I error rates. 
With respect to power, AFC is either the most powerful test or has similar power with the 
most powerful test under a variety of simulation scenarios. Additionally, the real data 
analysis results demonstrated that the proposed method has great potential in GWAS on 
complex diseases with multiple phenotypes such as COPD.  
AFC has several important advantages. First, it allows researchers to test genetic 
associations using standard GWAS software. Second, phenotypes of different types (e.g., 
dichotomous, ordinal, continuous) can be easily analyzed simultaneously. Third, since 
AFC is based on p-values obtained from standard univariate GWAS, it can not only test 
the association between multiple phenotypes and one genetic variant of interest, but also 
can test the association between multiple phenotypes and multiple genetic variants. For 
common variants, multiple-variant AFC can be applied based on p-values obtained in 
standard univariate GWAS for each variant and each phenotype. For rare variants, we can 
first combine genotypes of rare variants by giving different weights, hoping that we give 
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big weights to the variants having strong associations with the phenotypes. Then, we can 
apply AFC to test the association between the combined genotypes and multiple 
phenotypes. In conclusion, we showed that our proposed method provides a useful 
framework for joint analysis of multiple phenotypes in association studies. 
         It is well known that the effect sizes of identified variants are often small and that a 
large sample size is necessary to ensure sufficient power to detect such variants. A 
common strategy to increase sample size is to perform a meta-analysis by combining 
summary statistics from a series of studies. The proposed AFC method can be applied to 
meta-analysis. Suppose that there are 𝐿 independent studies containing the variant of 
interest and each study has 𝐾 phenotypes. Let 𝑇(L,… , 𝑇@L denote the summary statistics 
from the 𝑙/0 study. Suppose that 𝑇L = (𝑇(L, … , 𝑇@L)-~𝑁(0, ΣL) under the null hypothesis, 
where ΣL can be estimated from the values of  𝑇L for all independent SNPs in the GWAS 
from the 𝑙/0 study (Zhu et al., 2015b). Then, 𝑇 = (𝑇(-, … , 𝑇°-)-~𝑁(0, Σ), where Σ =
𝑑𝑖𝑎𝑔(Σ(,… , Σ°). From 𝑇, we can calculate the corresponding p-values 𝑃 = (𝑃(-, … , 𝑃°-)-, 
where 𝑃L = (𝑝(L, … , 𝑝@L)-. The AFC test statistic is based on the p-values 𝑃. In the 
permutation procedure, we can generate 𝑇 according to the distribution 𝑁(0, Σ) and then 
we can calculate the p-values 𝑃 in each permutation.  
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1.5   Tables and Figures 
Table 1.1. The estimated type I error rates of the proposed method for MAF equals 0.3.	  𝛼 
is the significance level. 10,000 replicates are used in the simulations. 
𝜶  Sample size 
Scenario 
1 2 3 4 5 6 
0.01 
1000 0.0088 0.0110 0.0105 0.0083 0.0083 0.0108 
2000 0.0095 0.0107 0.0094 0.0083 0.0098 0.0110 
0.001 
1000 0.0008 0.0015 0.0012 0.0008 0.0007 0.0012 





Table 1.2. The estimated type I error rates of the proposed method that mimic GWAS. α 
is the significance level.  
𝜶 Scenario 1 2 3 4 5 6 
1.00× 10 1.02× 10 1.06× 10 0.94× 10 1.03× 10 1.00× 10 1.05× 10 
1.00× 10 1.03× 10 1.20× 10 0.80× 10 0.97× 10 1.20× 10 0.82× 10 





Table 1.3. Significant SNPs and the corresponding p-values in the analysis of 
COPDGene. The p-values of AFC, Tippett, FC, and SUMSCORE are evaluated using 
109 permutations. The p-values of TATES, MANOVA, and MultiPhen are evaluated 
using asymptotic distributions. The graying out p-values indicate the p-values >





Figure 1.1. Power comparisons of the 7 tests for power as a function of effect size (𝛽) 
under the 6 scenarios. The total number of phenotypes is 20. The sample size is 1,000. 
MAF is 0.3. The factor loadings are 0.75. In scenarios 2, 3 and 4, the factorial correlation 
( 𝜌\K) is 0.1. In scenario 6, the phenotypic correlation (𝜌h0k) is 0.1. The powers are 





Figure 1.2. Power comparisons of the 7 tests for power as a function of factorial 
correlation (𝜌\K) under scenarios 2 to 4, and as a function of phenotypic correlation 
(𝜌h0k) under scenario 6. The total number of phenotypes is 20. The sample size is 1,000. 
MAF is 0.3. The factor loadings are 0.75. In scenarios 2 and 3, the effect size (𝛽) is 0.2. 
In scenario 4, the effect size (𝛽) is 0.3. In scenario 6, the effect size (𝛽) is 0.1. The 





Figure 1.3. Power comparisons of the 7 tests for power as a function of effect size (𝛽) 
under scenario 2. The total number of phenotypes is 20. The sample size is 1,000. MAF is 
0.3. The factor loadings are 0.75. The factorial correlation ( 𝜌\K) is 0.1. The powers are 
evaluated at 10¹ significance level while p-values of AFC, FC, Tippet, and 









2   Joint Analysis of Multiple Phenotypes in Association 
Studies Using Allele-based Clustering Approach for Non-
Normal Distributions 
In the study of complex diseases, several correlated phenotypes are usually measured. 
There is also increasing evidence showing that testing the association between a single-
nucleotide polymorphism (SNP) and multiple-dependent phenotypes jointly is often more 
powerful than analyzing only one phenotype at a time. Therefore, developing statistical 
methods to test for genetic association with multiple phenotypes has become increasingly 
important. In this study, we develop an Allele-Based Clustering (ABC) approach for the 
joint analysis of multiple non-normal phenotypes in association studies. In the ABC 
method, we consider the alleles at a SNP of interest as a dependent variable with two 
classes, and the correlated phenotypes as predictors to predict the alleles at the SNP of 
interest. We perform extensive simulation studies to evaluate the performance of the 
ABC method and compare the power of the ABC method with the powers of Adaptive 
Fisher’s Combination test (AFC), Trait-based Association Test that uses Extended Simes 
procedure (TATES), Fisher’s Combination test (FC), the standard MANOVA, and the 
joint model of Multiple Phenotypes (MultiPhen). Our simulation studies show that the 
proposed method has correct type I error rates and is much more powerful than other 
methods for some non-normal distributions.   
 
2.1   Background 
In the study of a complex disease, data on multiple phenotypes are often collected to have 
a better understanding of the disease. For example, cardiovascular disease (CVD) is 
characterized by high levels of both low-density serum lipoprotein levels (LDL) and 
systolic blood pressure (SBP) (Newman III et al., 1986; Majumdar et al., 2015); Chronic 
obstructive pulmonary disease (COPD) is one of the most common lung diseases 
characterized by reduced expiratory airflow, symptoms of cough, sputum production, and 
dyspnea (Casaburi et al., 2002); Thromboembolic disease is characterized by the 
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intermediate correlated phenotypes such as Factor VII, VIII, IX, XI, XII, and von 
Willebrand factor (Germain et al.,2011; Ray et al. 2016; Souto et al. 2000).  
Statistical methods for detecting association using multivariate phenotypes have 
been developed. These methods can be roughly divided into two groups: univariate 
methods and multivariate methods. Univariate methods are based on univariate analyses 
and combine the results of univariate analyses. Multivariate methods are based on models 
that jointly model multiple phenotypes. Univariate methods are popular in practice 
because it is much easier to construct a univariate association test statistic than a 
multivariate association test statistic. Recently, several univariate methods have appeared 
to explore the genetic association with multiple phenotypes by considering the correlation 
structure among phenotypes (Kwak & Pan, 2016; Liang et al., 2016; van der Sluis et al., 
2013; Yang et al., 2016). Kwak and Pan (2016) proposed an adaptive gene-based test and 
a pathway-based test for association analysis of multiple phenotypes with summary 
statistics from genome-wide association studies (GWAS). The Trait-based Association 
Test that uses Extended Simes procedure (TATES) combines p-values obtained in 
standard univariate GWAS while correcting for the correlation between p-values (van der 
Sluis et al., 2013). Adaptive Fisher’s Combination test (AFC) combines p-values 
obtained in standard univariate GWAS by using the optimal number of p-values which is 
determined by the data (Liang et al., 2016).  
Comparing univariate methods with multivariate methods, univariate methods 
may lose power since univariate methods ignore the extra information by analyzing 
multiple phenotypes in one unified analysis. Recently, several multivariate methods have 
been developed (Marchini et al., 2007; Galesloot et al., 2014; Zhou and Stephens, 2014; 
Korte et al., 2012; Casale et al., 2015; Zhang et al., 2014; Yan et al., 2013; O'Reilly et al., 
2012; Tang and Ferreira, 2012; Aschard et al., 2014; Lange et al., 2004; Klei et al., 2008; 
Zhou et al., 2015). However, most of the multivariate methods are based on the 
assumption of normality for phenotypes. In this article, we develop a novel multivariate 
method, named an Allele-Based Clustering (ABC) approach, for the joint analysis of 
multiple non-normal phenotypes. The ABC approach is nonparametric in that it does not 
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assume any particular genetic models. Using extensive simulation studies, we evaluate 
the performance of the proposed method and compare the power of the proposed method 
with the powers of AFC (Liang et al., 2016), TATES (van der Sluis et al., 2013), Fisher’s 
Combination test (FC) (Yang et al., 2016), MANOVA (Cole et al., 1994), and MultiPhen 
(O’Reilly et al., 2012). Our simulation studies show that the proposed method has correct 
type I error rates and is either the most powerful test or comparable with the most 
powerful tests for all simulation scenarios.  
 
2.2   Methods 
2.2.1   Allele-Based Clustering Method 
Consider a sample of 𝑁 unrelated individuals. Each individual has 𝑀 phenotypes. We 
propose an allele-based method to test the null hypothesis 𝐻<: none of the 𝑀 phenotypes 
are associated with a SNP of interest. Denote 𝑌3,f as the 𝑚/0 phenotype of the 𝑖/0 
individual. For the SNP of interest, we use 𝐴 (minor allele) and 𝑎 to denote the two 
alleles of this SNP. Because each individual has two alleles at the SNP of interest, we use 
𝑥?3( and 𝑥?3 to code the two alleles of the 𝑖/0 individual. If the genotype of the 𝑖/0 
individual is	  𝐴𝐴, we define	  𝑥?3( = 𝑥?3 = 1; if the genotype is	  𝑎𝑎, we define	  𝑥?3( =
𝑥?3 = 0; and if the genotype is	  𝐴𝑎, we define	  𝑥?3( = 1 and	  𝑥?3 = 0. We define that each 
allele of each individual has 𝑀 phenotypes and define the 	  𝑚/0	   phenotype corresponding 
to the two alleles 𝑥?3( and 𝑥?3 of the 𝑖/0 individual as 𝑦?3(,f and 𝑦?3,f, where 
𝑦?3(,f = 𝑦?3,f = 𝑌3,f. Hence, the total number of observations in the allele-based data 
is	  2𝑁. We reindex the 2𝑁 allele-based data and use index 𝑗 to denote the 𝑗/0  allele-based 
data. Therefore, 𝑦 ,f and 𝑥  denote the 𝑗/0  allele-based phenotypic and genotypic data. 
We develop an Allele-Based Clustering (ABC) approach based on k-fold cross-
validation for joint analysis of multiple phenotypes in association studies. In the ABC 
method, we consider the alleles at the SNP of interest as a dependent variable with two 
classes, and the correlated phenotypes as predictors to predict the alleles at the SNP of 
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interest. In the k-fold cross-validation (in this study, 𝑘 = 10), the 2𝑁 allele-based 
phenotypic and genotypic data are divided into 𝑘 mutually exclusive groups. We use each 
of the 𝑘 groups as the testing set and the other 𝑘 − 1 groups as the training set. For each 
pair of the testing and training sets, we use the training set to calculate the centers of the 
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 and use these centers to predict the alleles in 
the corresponding testing set, where 𝑦¼f
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testing set, we calculate the Euclidean distance between 𝑦  and 𝑦¼(<), and	  𝑦 	  	  and 
𝑦¼((),	  respectively. If  is closer to  than to , we predict the corresponding  as 
; otherwise, we predict the corresponding  as . In this way, each  has a 
predicted value  for . For the SNP of interest, let  and  denote the 
allele frequency of 𝑎 and 𝐴, respectively. For a given allele at the SNP of interest, the 
probability that we predict this allele by chance as allele 𝑎 is  and the probability that 
we predict this allele by chance as allele 𝐴 is . Therefore, we define the prediction 
accuracy as , where for a set 𝐷, #𝐷 denotes 
the number of elements in set 𝐷. We use  as the test statistic to test the association 
between the 𝑀 phenotypes and the SNP. 
First, we delete those phenotypes that have weak associations with the SNP of 
interest based on the univariate analysis. For a given threshold 𝑡, 0 < 𝑡 < 1, we delete 
phenotypes with 𝑝f > 𝑡 that means we select phenotypes with 𝑝f ≤ 𝑡, where 𝑝f is the 
p-value to test the association between the 𝑚/0 phenotype and the SNP. To test the 
association between the 𝑚/0 phenotype and the SNP, we use the score test statistic under 
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the logistic model logitD𝜋 H = 𝛼f + 𝑦 ,f𝛽f, 𝑗 = 1, 2, . . . , 2𝑁, where	  𝜋  =
PrD𝑥  = 1Æ𝑦 ,fH. The score test statistic to test the null hypothesis 𝐻<: 𝛽f = 0 is given by 
𝑆f = 𝑈f? /𝑉f, where 𝑈f = ∑ 𝑦 ,fD𝑥  − ?̅?H?Ë I( , 𝑉f =
(
?Ë
∑ D𝑦 ,f − 𝑦¼fH
??Ë
 I( ∑ D𝑥  −?Ë I(
?̅?H
?
, ?̅? = (
?Ë
∑ 𝑥 ?Ë I( , and 𝑦¼f =
(
?Ë
∑ 𝑦 ,f?Ë I( . Under the null hypothesis, 𝑆f follows a chi-
square distribution with 1 degree of freedom. Let  denote the p-value of  to test 
the association between the 𝑚/0 phenotype and the SNP of interest. For a given threshold 
𝑡, 0 < 𝑡 < 1, we denote the prediction accuracy using the selected phenotypes as 𝑇ÌÍ . 
Let  𝑃/ denote the p-value of the statistic 𝑇ÌÍ . Our test statistic of ABC approach is given 
by  
𝑇Ì` = minÎ 𝑃/. 
𝑇Ì`  can be obtained by a simple grid search across a range of 𝑡. We choose grids 
 such that . In this study, we use 
. By a grid search,  
.  
We use the following permutation procedure to evaluate the p-values of . 
1.   In each permutation, we randomly shuffle the genotypes and recalculate 
. Suppose that we perform 𝐵 times of permutations. Let  (𝑏 =
0,1,… , 𝐵) denote the value of  based on the 𝑏/0  permuted data, where 𝑏 = 0 
represents the original data.  
2.   We transfer  to  by  
                             (1) 
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3.   Let . Then, the p-value of  is given by 
                                   (2) 
 
2.2.2   Comparison of Methods 
We compare the performance of our ABC method with those of AFC (Liang et al., 2016), 
TATES (van der Sluis et al., 2013), FC (Yang et al., 2016), MANOVA (Cole et al., 
1994), and MultiPhen (O’Reilly et al., 2012). 
 
2.3   Results 
2.3.1   Simulation Studies  
We generate genotype data at a SNP according to a minor allele frequency (MAF) 
(MAF=0.3 in all simulation studies) under Hardy-Weinberg equilibrium. Based on the 
genotype data, phenotypes are generated similar to that of Liang et al. (Liang et al., 2016) 
and van der Sluis et al. (van der Sluis et al., 2013). The phenotypic correlation structures 
(the phenotypes are divided into several groups (factors) and the within-group correlation 
is larger than the between-group correlation) are also similar to that of UK10K (UK10K 
Consortium, 2015).  
In the following six scenarios, we use the following notations. Denote 𝑌f =
D𝑌(,f, 𝑌?,f,… , 𝑌Ë,fH
-
 as the 𝑚/0 phenotype of 𝑁 individuals and 𝐺 = (𝑔(, 𝑔?,… , 𝑔Ë)- as 
the genotypic score of 𝑁 individuals at the SNP. Let 𝑅 denote the number of factors and 
(𝑓(,… , 𝑓)-~𝑀𝑉𝑁(0, 𝚺), where 𝚺 is a correlation matrix with all off-diagonal elements 
equal to 𝜌\K  and 𝜌\K  is the correlation between any two factors. 𝛽 is the effect size; 𝑎 is a 
factor loading; 𝜀f = (𝜀(f, … , 𝜀Ëf)𝑻 and 𝜀3f	  (𝑖 = 1,… , 𝑁;𝑚 = 1,… ,𝑀) are random 
errors.  
( ) ( ) ( ){ }1min , , Sb b bABC t tT P P= … ABCT





Scenario 1: we simulate 𝑀 phenotypes by  
𝑌f = 𝑎𝛽𝐺 + 𝜀f for 𝑚 = 1,2,… ,𝑀                                         (3) 
Scenario 2: consider a 4-factor model (𝑅 = 4) with the SNP effect on the fourth 
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                     (4) 
Scenario 3: consider a 2-factor model (𝑅 = 2) with the SNP effect on the second 
factor. We simulate 𝑀 phenotypes using  
𝑌f = £
𝑎𝑓( + 𝜀f	  	  	  	  	  	  	  for	  𝑚 = 1,… ,

?




                        (5)                                        
Scenario 4: consider a 4-factor model (𝑅 = 4) with the SNP effect on the 𝑀/0 
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Scenario 5: consider a 2-factor model (𝑅 = 2) with the SNP effect on the 𝑀/0 
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Scenario 6: consider an 𝑀-factor model (𝑅 = 𝑀) with the SNP effect on all 
phenotypes. We simulate 𝑀 phenotypes using  
𝑌f = 𝑎(𝑓f + 𝛽𝐺) + 𝜀f for 𝑚 = 1,2,… ,𝑀                               (8) 
In scenarios 2-6, the within-factor correlation is 𝑎? and between-factor correlation 
is 𝑎?𝜌\K . In scenarios 1-6, we consider random errors having the following four non-
normal distributions: two log-normal distributions (  and 
), Student’s t-distribution (𝑡(2)), and Inverse-gamma distribution 
(Inverse-gamma(2,1)). We also consider random errors following the standard normal 
distribution. To evaluate type I error rates, we generate phenotypic values independent of 
genotypes by assigning  𝛽 = 0. To evaluate power, we generate phenotypic values 
according to the six scenarios described above. In type I error evaluations and power 
comparisons, MAF is 0.3, the total number of phenotypes (𝑀) is 8, the sample size (𝑁) is 
1,000, the factor loading (𝑎) is 0.75, and the factorial correlation (𝜌\K) conditional on 
genotypes is 0.1. 
 
2.3.2   Simulation Results  
In each simulation scenario, the p-values of the proposed test (ABC), AFC, and FC are 
estimated using 1,000 permutations and the p-values of TATES, MANOVA, and 
MultiPhen are estimated using asymptotic distributions. 
For type I error evaluation, we consider different distributions of random errors, 





simulation scenario, the type I error rates of all of the six tests are evaluated using 1,000 
replicated samples. For 1,000 replicated samples, the 95% confidence intervals (CIs) for 
the type I error rates at the nominal levels 0.01 and 0.05 are (0.0038, 0.0162) and 
(0.0365, 0.0635), respectively. The estimated type I error rates for random errors 
following Student’s 𝑡(2) distribution, Inverse-gamma(1,2) distribution, 
 distribution,  distribution, and the standard normal 
distribution are summarized in Tables 2.1 to 2.5, respectively. From these tables, we can 
see that most of the estimated type I error rates of ABC, AFC, FC, TATES, and 
MANOVA are within the 95% CIs and those type I error rates not within 95% CIs are 
very close to the bound of the corresponding 95% CI, which indicates that ABC, AFC, 
FC, TATES, and MANOVA are valid. MultiPhen for Inverse-gamma(1,2) distribution 
has little inflated type I error rates.  
The powers of all tests are evaluated using 1,000 replicated samples at 1% 
significance level. Figures 2.1 to 2.5 provide the power comparisons of the six tests 
(ABC, AFC, TATES, FC, MANOVA, and MultiPhen) for the power as a function of the 
effect size based on the six scenarios for 8 phenotypes. Figure 2.1 shows that when 
random errors follow a Student’s t distribution, ABC is the most powerful test in all the 
scenarios and is much more powerful than other methods. Figure 2.2 shows that when 
random errors follow an Inverse-gamma distribution, ABC is the most powerful test in all 
the scenarios and is much more powerful than the other methods when genotypes directly 
impact on a portion of phenotypes (scenarios 2-5). Figure 2.3 shows that when random 
errors follow a Log-normal distribution, ABC is the most powerful test when genotypes 
directly impact on a portion of phenotypes (scenarios 2-5) and is comparable to the most 
powerful one when genotypes directly impact on all phenotypes (scenarios 1 and 6). To 
show the robustness of ABC to phenotype outliers, we generate random errors following 
a Log-normal distribution with a variance 5 times as that in Figure 2.3. As shown in 
Figure 2.4, increasing variance 5 times, the pattern of power comparisons is still the same 
as that in Figure 2.3. We also provide power comparisons when random errors follow a 
standard normal distribution (Figure 2.5). As expected, ABC loses some power 
( )log-norm 0,1 ( )5log-norm 0,1
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comparing with that when random errors follow non-normal distributions, but is still 
more powerful than TATES for scenarios 1 and 6, more powerful than FC for scenarios 4 
and 5, and more powerful than MANOVA and MultiPhen for scenario 3. 
 
2.4   Discussion 
In GWAS for complex diseases, the association between a SNP and each phenotype is 
usually weak. Combining multiple related phenotypes can increase the power to identify 
causal SNPs, thus is a practically important area that requires methodology work. So far, 
existing methods for associations of multiple phenotypes primarily focus on the 
phenotypes with a normal distribution. However, when the normal assumption is 
violated, these methods may not control type I error rates or may lose power (Majumdar 
et al., 2015).  
In this study, we introduced an Allele-Based Clustering (ABC) approach for joint 
analysis of multiple non-normal distributed phenotypes in association studies. The ABC 
approach is nonparametric in that it does not assume any particular genetic models and 
there are no parameters need to be estimated. We use a data-driven approach to select 
phenotypes that are associated with a SNP and use these phenotypes to predict the alleles 
at the SNP by using Euclidean distance. Besides Euclidean distance, we can also use 
other similarity or dissimilarity measures to predict the alleles at a SNP, such as 
Minkowski distance, Mahalanobis distance, correlation coefficient, and cosine measure.  
We use extensive simulations to assess the performance of ABC. We are able to 
demonstrate that ABC has correct type I error rates and is much more powerful than other 
methods for some non-normal distributions. Therefore, our simulations show that ABC is 
especially useful for non-normal data and it truly adds to the geneticist’s toolbox. 
Moreover, ABC does not estimate any parameters and does not assume any particular 
models. It provides another way for analyzing multiple phenotypes simultaneously. In the 
method section, we describe our methods without considering covariates. If there are 
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covariates need to be considered, we can use the following approach to incorporate 
covariates in the ABC approach. Suppose that we have 𝑝 covariates. Let D𝑧3(, … , 𝑧3hH
-
 
denote the covariates of the 𝑖/0 individual. We can adjust the effects of covariates by 
applying the linear regression model 𝑌3,f = 𝑎< + 𝑎(f𝑧3( +⋯+ 𝑎hf𝑧3h + 𝜀3f  and using 
the residual of 𝑌3,f  to replace 𝑌3,f in the ABC approach. Although using the regular 
linear regression to regress effects of covariates out is more suited for normally 
distributed data, it can also be applied to non-normally distributed data. For examples, to 
correct for population stratification, Price et al. (2006) used the regular linear regression 
to regress effects of covariates out for a qualitative phenotype and genotypes (both a 
qualitative phenotype and genotypes are non-normally distributed data); to adjust effects 
of covariates in rare variant association studies, Sha et al. (2012) also used the regular 
linear regression to regress effects of covariates out for a qualitative phenotype and 
genotypes. 
The computation time required for running ABC depends on the sample size, the 
number of phenotypes, the number of folds in cross-validation, and the number of 
permutations. The running time of ABC with 1,000 permutations on the data set with 
10,000 individuals, 8 phenotypes, and 10-fold cross-validation on a laptop with 4 Intel 
Cores @ 2.00GHz and 4 GB memory is no more than 2.4s. To perform genome-wide 
studies, we can first select SNPs that show evidence of association based on a small 
number of permutations (e.g. 1,000), and then a large number of permutations are used to 





2.5   Tables and Figures 
Table 2.1. The estimated type I error rates of the 6 tests under Student’s 𝑡(2) 
distribution. MAF is 0.3. α is the significance level. The total number of phenotypes (𝑀) 
is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 0.75. The factorial correlation 
(𝜌\K) conditional on genotypes is 0.1. The number of replications is 1,000. The type I 
error rates in bold indicate the values out of the bounds of the 95% CIs. 
𝜶 Method 
Scenario 
1 2 3 4 5 6 
0.01 
ABC 0.009 0.010 0.015 0.012 0.008 0.011 
AFC 0.009 0.010 0.015 0.013 0.015 0.015 
TATES 0.007 0.007 0.011 0.007 0.007 0.007 
FC 0.009 0.011 0.011 0.008 0.011 0.018 
MANOVA 0.008 0.010 0.009 0.008 0.008 0.013 
MultiPhen 0.014 0.007 0.014 0.008 0.012 0.019 
0.05 
ABC 0.039 0.042 0.055 0.048 0.045 0.057 
AFC 0.050 0.058 0.051 0.050 0.049 0.049 
TATES 0.042 0.045 0.043 0.041 0.053 0.044 
FC 0.053 0.054 0.056 0.046 0.045 0.048 
MANOVA 0.050 0.051 0.046 0.04 0.044 0.046 





Table 2.2. The estimated type I error rates of the 6 tests under Inverse-gamma(1,2) 
distribution. MAF is 0.3. α is the significance level. The total number of phenotypes (𝑀) 
is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 0.75. The factorial correlation 
(𝜌\K) conditional on genotypes is 0.1. The number of replications is 1,000. The type I 
error rates in bold indicate the values out of the bounds of the 95% CIs. 
𝛂 Method 
Scenario 
1 2 3 4 5 6 
0.01 
ABC 0.016 0.015 0.016 0.007 0.013 0.013 
AFC 0.012 0.019 0.009 0.010 0.014 0.007 
TATES 0.009 0.009 0.009 0.008 0.015 0.008 
FC 0.012 0.016 0.006 0.006 0.013 0.005 
MANOVA 0.009 0.009 0.008 0.009 0.014 0.004 
MultiPhen 0.010 0.020 0.013 0.013 0.019 0.017 
0.05 
ABC 0.063 0.056 0.059 0.041 0.054 0.050 
AFC 0.056 0.065 0.048 0.048 0.061 0.046 
TATES 0.040 0.050 0.035 0.035 0.051 0.042 
FC 0.055 0.061 0.046 0.052 0.062 0.046 
MANOVA 0.053 0.058 0.041 0.045 0.050 0.045 





Table 2.3. The estimated type I error rates of the 6 tests under Log-norm(0,1) 
distribution. MAF is 0.3. α is the significance level. The total number of phenotypes (𝑀) 
is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 0.75. The factorial correlation 
(𝜌\K) conditional on genotypes is 0.1. The number of replications is 1,000. The type I 
error rates in bold indicate the values out of the bounds of the 95% CIs. 
𝛂 Method 
Scenario 
1 2 3 4 5 6 
0.01 
ABC 0.014 0.012 0.01 0.007 0.009 0.006 
AFC 0.013 0.013 0.009 0.013 0.012 0.012 
TATES 0.011 0.013 0.006 0.006 0.008 0.008 
FC 0.008 0.010 0.009 0.013 0.008 0.010 
MANOVA 0.007 0.011 0.009 0.011 0.012 0.009 
MultiPhen 0.014 0.011 0.005 0.015 0.012 0.010 
0.05 
ABC 0.057 0.057 0.050 0.054 0.049 0.050 
AFC 0.040 0.06 0.038 0.056 0.040 0.046 
TATES 0.043 0.046 0.038 0.049 0.037 0.048 
FC 0.037 0.057 0.038 0.053 0.050 0.044 
MANOVA 0.039 0.055 0.042 0.048 0.041 0.041 





Table 2.4. The estimated type I error rates of the 6 tests under 
distribution. MAF is 0.3. α is the significance level. The total number of phenotypes (𝑀) 
is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 0.75. The factorial correlation 
(𝜌\K) conditional on genotypes is 0.1. The number of replications is 1,000. The type I 
error rates in bold indicate the values out of the bounds of the 95% CIs. 
𝛂 Method 
Scenario 
1 2 3 4 5 6 
0.01 
ABC 0.011 0.012 0.014 0.008 0.011 0.012 
AFC 0.015 0.013 0.010 0.014 0.008 0.014 
TATES 0.013 0.012 0.017 0.005 0.011 0.012 
FC 0.014 0.010 0.010 0.013 0.006 0.012 
MANOVA 0.014 0.009 0.008 0.013 0.006 0.011 
MultiPhen 0.017 0.014 0.014 0.017 0.011 0.012 
0.05 
ABC 0.052 0.058 0.054 0.045 0.049 0.049 
AFC 0.053 0.050 0.049 0.051 0.049 0.053 
TATES 0.043 0.056 0.053 0.039 0.048 0.052 
FC 0.066 0.055 0.044 0.050 0.045 0.049 
MANOVA 0.064 0.058 0.041 0.046 0.046 0.044 






Table 2.5. The estimated type I error rates of the 6 tests under the standard normal 
distribution. MAF is 0.3. α is the significance level. The total number of phenotypes (𝑀) 
is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 0.75. The factorial correlation 
(𝜌\K) conditional on genotypes is 0.1. The number of replications is 1,000. The type I 
error rates in bold indicate the values out of the bounds of the 95% CIs. 
𝛂 Method 
Scenario 
1 2 3 4 5 6 
0.01 
ABC 0.007 0.012 0.011 0.009 0.013 0.008 
AFC 0.015 0.012 0.008 0.006 0.007 0.011 
TATES 0.012 0.015 0.009 0.012 0.005 0.009 
FC 0.013 0.014 0.009 0.007 0.007 0.007 
MANOVA 0.014 0.008 0.009 0.008 0.008 0.008 
MultiPhen 0.010 0.010 0.012 0.007 0.009 0.008 
0.05 
ABC 0.047 0.052 0.049 0.051 0.054 0.051 
AFC 0.062 0.048 0.049 0.042 0.054 0.045 
TATES 0.050 0.052 0.051 0.042 0.053 0.048 
FC 0.050 0.052 0.040 0.046 0.051 0.049 
MANOVA 0.052 0.050 0.055 0.051 0.057 0.044 





Figure 2.1. Power comparisons of the 6 tests for power as a function of effect size (𝛽) for 
Student’s 𝑡(2) distribution under the 6 scenarios. MAF is 0.3. The total number of 
phenotypes (𝑀) is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 0.75. The 
factorial correlation (𝜌\K) conditional on genotypes is 0.1. The powers are evaluated at 





Figure 2.2. Power comparisons of the 6 tests for power as a function of effect size (𝛽) for 
Inverse-gamma (𝛼 = 2, 𝛽 = 1) distribution under the 6 scenarios. MAF is 0.3. The total 
number of phenotypes (𝑀) is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 
0.75. The factorial correlation (𝜌\K) conditional on genotypes is 0.1. The powers are 





Figure 2.3. Power comparisons of the 6 tests for power as a function of effect size (𝛽) for 
Log-norm (0, 1) distribution under the 6 scenarios. MAF is 0.3. The total number of 
phenotypes (𝑀) is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 0.75. The 
factorial correlation (𝜌\K) conditional on genotypes is 0.1. The powers are evaluated at 





Figure 2.4. Power comparisons of the 6 tests for power as a function of effect size (𝛽) for 
 distribution under the 6 scenarios. MAF is 0.3. The total number of 
phenotypes (𝑀) is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 0.75. The 
factorial correlation (𝜌\K) conditional on genotypes is 0.1. The powers are evaluated at 






Figure 2.5. Power comparisons of the 6 tests for power as a function of effect size (𝛽) for 
Normal (0, 1) distribution under the 6 scenarios. MAF is 0.3. The total number of 
phenotypes (𝑀) is 8. The sample size (𝑁) is 1,000. The factor loading (𝑎) is 0.75. The 
factorial correlation (𝜌\K) conditional on genotypes is 0.1. The powers are evaluated at 





3   A Hierarchical Clustering Method for Dimension 
Reduction in Joint Analysis of Multiple Phenotypes 
Genome-wide association studies (GWAS) have become a very effective research tool to 
identify genetic variants of underlying various complex diseases. In spite of the success 
of GWAS in identifying thousands of reproducible associations between genetic variants 
and complex disease, in general, the association between genetic variants and a single 
phenotype is usually weak. It is increasingly recognized that joint analysis of multiple 
phenotypes can be potentially more powerful than the univariate analysis, and can shed 
new light on underlying biological mechanisms of complex diseases. In this study, we 
develop a novel variable reduction method using hierarchical clustering method (HCM) 
for joint analysis of multiple phenotypes in association studies. The proposed method 
involves two steps. The first step applies a dimension reduction technique by using a 
representative phenotype for each cluster of phenotypes. Then, existing methods are used 
in the second step to test the association between genetic variants and the representative 
phenotypes rather than the individual phenotypes. We perform extensive simulation 
studies to compare the powers of MANOVA, MultiPhen, and TATES using HCM with 
those of without using HCM. Our simulation studies show that using HCM is more 
powerful than without using HCM in most scenarios. We also illustrate the usefulness of 
using HCM by analyzing a whole-genome genotyping data from a lung function study. 
 
3.1   Background 
The successful applications of genome-wide association studies (GWAS) to numerous 
complex diseases established a large number of genetic associations (Lutz et al., 2017). 
Through GWAS, numerous genes have been shown to affect multiple phenotypes and yet 
the effect size on each phenotype is small for complex diseases (Yang et al., 2017). For 
example, multiple GWAS have found significant signals in the chromosome 15q25 
region associated with lung cancer (Chen et al., 2015), chronic obstructive lung disease 
(COPD) (Cho et al., 2014), emphysema (Cho et al., 2015), and cigarette smoking 
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(Hancock et al., 2015). 
Simultaneous testing of multiple phenotypes has been widely recognized as a 
valuable approach complementary to single phenotype tests. There are two main reasons: 
one is to increase statistical power, and the other is to shed light on underlying biology to 
possibly repurpose the use of existing drugs (Deng & Pan, 2017). Therefore, there is an 
increasing interest in joint analysis of multiple phenotypes with many new tests being 
recently proposed (Aschard et al., 2014; Casale et al., 2015; Cole et al., 1994; Galesloot 
et al., 2014; Klei et al., 2008; Korte et al., 2012; Lange et al., 2004; Liang et al., 2016; 
Marchini et al., 2007; O'Reilly et al., 2012; Tang & Ferreira, 2012; Wang et al., 2016; 
Yan et al., 2013; Zhang et al., 2014; Zhou & Stephens, 2014; Zhou et al., 2015; Zhu et 
al., 2015a).  
Existing methods for joint analysis of multiple phenotypes roughly fall into three 
categories: regression methods, combining test statistics from univariate analyses, and 
variable reduction methods (Yang & Wang, 2012). In the first category, regression 
methods, there are three different approaches for analyzing the association of a genetic 
variant with multiple phenotypes: mixed effects models (Bates & DebRoy, 2004; Yan et 
al., 2013), generalized estimating equations (Liang & Zeger, 1986), and frailty models 
(Therneau et al., 2003). Tests that fall into the second category, combining test statistics 
from univariate analyses, conduct a univariate analysis first and then aggregate univariate 
test statistics. This approach is simple and feasible for meta-analyses (Schaid et al., 2016; 
Yang et al., 2016). Recently, many methods of combining test statistics from univariate 
analyses have been developed to explore the genetic association with multiple 
phenotypes by considering the correlation structure among phenotypes (Kwak & Pan, 
2016; Liang et al., 2016; Van der Sluis et al., 2013; Yang et al., 2016). In the last 
category, tests based on variable reduction methods are roughly depending on three 
dimension reduction techniques. The first one is the principal component analysis of 
phenotypes (PCP) (Aschard et al., 2014). In PCP, the first few principal components 
(PCs) explaining most of the total phenotype variance are tested for association with a 
genetic variant, and the remaining components are not analyzed. However, Aschard et al. 
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(2014) showed that considering only the first few PCs often causes low power, whereas 
considering all PCs can improve the power. The second one is the canonical correlation 
analysis (CCA) (Tang & Ferreira, 2012). CCA searches for the linear combinations that 
maximize the correlation between two sets of multidimensional variables. It provides an 
efficient and powerful approach for both univariate and multivariate tests of association 
without the need for the permutation test. The last one is the principal component of 
heritability (PCH) (Klei et al., 2008; Ott & Rabinowitz, 1999; Wang et al., 2016a). PCH 
reduces multiple phenotypes to a linear combination of phenotypes that has the highest 
heritability among all linear combinations of phenotypes. 
In this article, we develop a novel variable reduction method called hierarchical 
clustering method (HCM) for joint analysis of multiple phenotypes. HCM is a dimension 
reduction technique by using a representative phenotype for each cluster of phenotypes, 
then using existing methods for joint analysis of multiple phenotypes to test the 
association between a genetic variant of interest and the representative phenotypes rather 
than the individual phenotypes. One way to understand the dimension reduction 
technique of HCM is that when one cluster consists of highly positively correlated 
phenotypes, any linear combination of the phenotypes within this cluster can represent 
the cluster reasonably well (Bühlmann et al., 2013; Shah & Samworth, 2013). HCM does 
not require phenotypes themselves, it only requires a dissimilarity matrix of the 
phenotypes. This dissimilarity matrix can be estimated from the values of summary 
statistics using all independent single-nucleotide polymorphisms (SNPs) in a GWAS 
(Zhu et al., 2015b). We use extensive simulation studies to show the validity of the 
proposed two-step method and to investigate the power. In particular, the performance of 
three existing methods using HCM, multivariate analysis of variance (MANOVA) (Cole 
et al., 1994), joint model of multiple phenotypes (MultiPhen) (O’Reilly et al., 2012), and 
trait-based association test that uses extended simes procedure (TATES) (Van der Sluis et 
al., 2013), is compared with that of without using HCM. Our simulation studies show that 
MANOVA, MultiPhen, and TATES using HCM have correct type I error rates and are 
more powerful than MANOVA, MultiPhen, and TATES without using HCM in most 
47 
 
scenarios. We also apply MANOVA, MultiPhen, and TATES with and without using 
HCM to COPDGene data to further demonstrate the usefulness of HCM.  
 
3.2   Methods 
3.2.1   Hierarchical Clustering Method for Joint Analysis of Multiple Phenotypes 
Consider a sample with 𝑛 unrelated individuals. Each individual has 𝐾 phenotypes. 
Denote 𝑌$ = (𝑦($,… , 𝑦+$)- as the 𝑘/0 phenotype of 𝑛 individuals and 𝒀 = (𝑌(, … , 𝑌@) as 
the 𝑛 × 𝐾 phenotype matrix. Denote 𝑋 = (𝑥(,… , 𝑥+)- as the genotypic score of 𝑛 
individuals at a genetic variant of interest, where 𝑥3 ∈ {0, 1, 2} is the number of minor 
alleles that the 𝑖/0 individual carries at the genetic variant.  
The proposed hierarchical clustering method (HCM) involves two steps. In the 
first step, we divide the 𝐾 phenotypes into 𝑀 clusters and use a representative phenotype 
for each of the 𝑀 clusters. In the second step, we apply existing methods to the 𝑀 
representative phenotypes rather than directly to the individual phenotypes to test the 
association between phenotypes and the variant. In the first step, we need to find a 
partition 𝒢 that partitions 𝐾 phenotypes into 𝑀 disjoint clusters 𝐺(, … , 𝐺, where 𝒢 =
{𝐺(,… , 𝐺} with ⋃ 𝐺ffI( = {1,… , 𝐾} and 𝐺f ∩ 𝐺ℓ𝓁 = ∅	  (𝑚 ≠ ℓ𝓁). In this article, we use 
a hierarchical clustering strategy to cluster the phenotypes. 
Strategies for hierarchical clustering generally fall into two types: agglomerative 
(bottom-up) and divisive (top-down). The agglomerative method starts with all 
phenotypes in their own cluster and merges the two clusters that have the smallest 
dissimilarity in each clustering iteration until there is only one single cluster left. The 
divisive method starts with all phenotypes in one cluster and splits the cluster into two 
that have the largest dissimilarity in each clustering iteration until all phenotypes are in 
their own cluster. Both methods can be described by a dendrogram which is frequently 
48 
 
used to illustrate the arrangement of the clusters produced by hierarchical clustering. We 
need a stopping criterion to cut the dendrogram into several clusters.  
In this study, we use the bottom-up hierarchical clustering method based on the 
dissimilarity matrix of the phenotypes. We define the dissimilarity matrix 𝐷 with entries 
𝑑3  = 1 − 𝑃3  , where 𝑃3   is the 𝑖𝑗/0 entry of 𝑃(𝒀) and 𝑃(𝒀) is the sample correlation 
matrix of 𝒀 = (𝑌(, … , 𝑌@). We choose the average linkage as the dissimilarity between 
two clusters. Hence, the dissimilarity between clusters 𝐺f and 𝐺ℓ𝓁 is given by 





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1) 
where |𝐺f| denote the number of phenotypes in 𝐺f. Using the bottom-up hierarchical 
clustering method, we start with each phenotype as a singleton cluster and then 
successively merge pairs of clusters with the smallest dissimilarity calculated by equation 
(1) until all clusters have been merged into a single cluster that contains all phenotypes. 
We refer the smallest dissimilarity in each iteration as the height of the merged cluster in 
the dendrogram. We determine the number of clusters in the HCM using a stopping 
criterion. The stopping criterion is similar to an established principle (Bühlmann et al., 
2013). Let ℎT denote the smallest dissimilarity between two clusters in iteration 𝑏 (𝑏 ≥
1) or the height of iteration 𝑏. We define: 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑏â = argmax
Tä(
(ℎT}( − ℎT)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2) 
Then, we choose the number of clusters identified at the iteration 𝑏â.   
Before we define the representative phenotype for each cluster, we first scale each 
phenotype. We define the representative phenotype for the 𝑚/0 cluster as the average 
phenotype values in the cluster, that is 





,𝑚 = 1, … ,𝑀	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3) 
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Let 𝒀å denote the 𝑛 × 𝑀 design matrix whose 𝑚/0 column is given by 𝑌¼(f). Then we 
apply existing methods to test the association between 𝒀å and 𝑋. 
 
3.2.2   Comparison of Methods 
We compare the performance of MANOVA, MultiPhen, and TATES with using HCM 
with that of without using HCM. We refer the ones with using HCM as HCMANOVA, 
HCMultiPhen, and HCTATES, respectively. Since principal component analysis (PCA) 
is a popular dimension reduction method, we also compare the performance of 
MANOVA, MultiPhen, and TATES using HCM with that of using the first few PCs of 
the phenotypes. We choose the number of PCs that explain 95% of the total variance of 
the phenotypes. We refer MANOVA, MultiPhen, and TATES using PCs as 
PCMANOVA, PCMultiPhen, and PCTATES, respectively.   
 
3.3   Results 
3.3.1   Simulation Studies  
To evaluate the type I error rates and powers of HCM, we generate genotypes at a genetic 
variant according to the minor allele frequency (MAF) under Hardy Weinberg 
equilibrium. Then, we generate 𝐾 phenotypes by the factor model (Wang et al., 2016a) 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  𝑦 = 𝜆𝑥 + 𝑐𝛾𝑓 + é1 − 𝑐? × 𝜀	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (4) 
where 𝑦 = (𝑦(, … , 𝑦@)- ; 𝑥 is the genotype score at the variant; 𝜆 = (𝜆(,… , 𝜆@)- is the 
vector of effect sizes of the genetic variant on the 𝐾 phenotypes;	  𝑓 is a vector of factors, 
𝑓 = (𝑓(, … , 𝑓)-~𝑀𝑉𝑁(0, Σ), Σ = (1 − 𝜌)𝐼 + 𝜌𝐴, 𝐴 is a matrix with elements of 1, 𝐼 is 
the identity matrix, 𝑅	  is the number of factors, and 𝜌 is the correlation between factors; 𝛾 
is a 𝐾 by 𝑅 matrix; 𝑐 is a constant number; and 𝜀 = (𝜀(,… , 𝜀@)- is a vector of residuals, 
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and 𝜀(, … , 𝜀@  are independent, and 𝜀$~𝑁(0,1) for 𝑘 = 1,… , 𝐾. Based on equation (4), 
we consider the following four models with different number of factors and different 
number of factors affected by genotypes. In the four models, the within-factor correlation 
is 𝑐? and the between-factor correlation is 𝜌𝑐?. 
Model 1: There is only one factor and genotypes impact on all phenotypes. That 
is, 𝑅 = 1, 𝜆 = 𝛽(1,2,… , 𝐾)-, and 𝛾 = (1,… ,1)-. 
Model 2: There are two factors and genotypes impact on one factor. That is, 𝑅 =








 for 𝑖 = 1, 2. 
Model 3: There are five factors and genotypes impact on two factors. That is, 𝑅 =
5, 𝜆 = (𝛽((, … , 𝛽($, 𝛽?(, … , 𝛽?$ , 𝛽(, … , 𝛽$ , 𝛽(,… , 𝛽$, 𝛽«(, … , 𝛽«$)-, and 𝛾 =




 for 𝑖 = 1,… ,5, 𝑘 = @
«
, 𝛽(( = ⋯𝛽($ =
𝛽?( = ⋯ = 𝛽?$ = 𝛽( = ⋯ = 𝛽$ = 0, 𝛽( = ⋯ = 𝛽$ = −𝛽, and (𝛽«(,… , 𝛽«$) =
?ò
$}(
(1,… , 𝑘). 
Model 4: There are five factors and genotypes impact on four factors. That is, 
𝑅 = 5, 𝜆 = (𝛽((,… , 𝛽($, 𝛽?(,… , 𝛽?$, 𝛽(,… , 𝛽$, 𝛽(, … , 𝛽$ , 𝛽«(, … , 𝛽«$)-, and 𝛾 =




 for 𝑖 = 1,… ,5, 𝑘 = @
«
, 𝛽(( = ⋯𝛽($ =
0, 𝛽?( = ⋯ = 𝛽?$ = 𝛽, 𝛽( = ⋯ = 𝛽$ = −𝛽, 𝛽( = ⋯ = 𝛽$ = −
?ò
$}(
(1,… , 𝑘), and 
(𝛽«(, … , 𝛽«$) =
?ò
$}(
(1,… , 𝑘). 
To evaluate type I error rates, we let 𝛽 = 0. To evaluate powers, we let 𝛽 > 0. In 
the simulation studies for evaluation of type I error rates and powers, we set MAF = 0.3, 




3.3.2   Simulation Results  
For each model, we estimate the p-values of all test statistics using their asymptotic 
distributions.  
For type I error evaluation, we consider different numbers of phenotypes, 
different significance levels, different sample sizes, and different models. For 10,000 
replicated samples, the 95% confidence intervals (CIs) for type I error rates at the 
nominal levels 0.05, 0.01, and 0.001 are (0.0457, 0.0543), (0.008, 0.012), and (0.0004, 
0.0016), respectively. The estimated type I error rates of HCMANOVA, HCMultiPhen, 
and HCTATES are summarized in Tables 3.1 to 3.3. The estimated type I error rates of 
PCMANOVA, PCMultiPhen, and PCTATES are summarized in Tables S1 to S3. From 
these tables, we can see that most of the estimated type I error rates are within the 95% 
CIs. In addition, the type I error rates outside of the 95% CIs are very close to the bounds 
of the corresponding 95% CI, which indicates that HCMANOVA, HCMultiPhen, 
HCTATES, PCMANOVA, PCMultiPhen, and PCTATES are valid tests.  
For power comparisons, we consider different numbers of phenotypes and 
different models. The powers of all tests are evaluated based on 1000 replications and 
5000 subjects at 5% significance level. Figure 3.1 and Figure 3.2 provide the power 
comparisons of the six tests (HCMANOVA, MANOVA, HCMultiPhen, MultiPhen, 
HCTATES, and TATES) for the power as a function of the effect size under the four 
models. We consider 20 phenotypes and 40 phenotypes in Figure 3.1 and Figure 3.2, 
respectively.  
These two figures show that (1) when the effect sizes of the genetic variant on 
phenotypes show no groups (Model 1), HCMANOVA, HCMultiPhen, and HCTATES 
are slightly less powerful than MANOVA, MultiPhen, and TATES, respectively, because 
in most replications, HCM clusters each phenotype in a singleton cluster; (2) when the 
effect sizes show some groups and have the same direction (Model 2), HCMANOVA, 
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HCMultiPhen, and HCTATES are much more powerful than MANOVA, MultiPhen, and 
TATES, respectively; (3) when the effect sizes show some groups and have different 
directions (Models 3 and 4), HCMANOVA and HCMultiPhen are more powerful than 
MANOVA and MultiPhen, respectively, but HCTATES is less powerful than TATES; 
(4) HCMANOVA and HCMultiPhen have similar power; MANOVA and MultiPhen 
have similar power; (5) HCTATES and TATES are much less powerful than other 
methods when genotypes directly impact on all phenotypes (Model 1). Figures A.1 and 
A.2 provide the power comparisons of HCM with those of using PCs of phenotypes that 
explain 95% of the total variance. These figures show that using HCM as a dimension 
reduction method is more powerful than using PCs that explain 95% of the total variance. 
We also set up an additional simulation model (Model S1) to compare the powers of 
MANOVA, MultiPhen, and TATES with those of HCMANOVA, HCMultiPhen, and 
HCTATES (Figure A.3). Figure A.3 shows that under Model S1, HCMANOVA, 
HCMultiPhen, and HCTATES are more powerful than MANOVA, MultiPhen, and 
TATES, respectively.      
In summary, the existing methods using HCM have correct type I error rates and 
are more powerful than or comparable with those without using HCM, and the existing 
methods using HCM are also more powerful than those using PCs of phenotypes as a 
dimension reduction method. 
 
3.3.3   Real Data Analysis  
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease 
including chronic bronchitis, emphysema, non-reversible asthma, and some forms of 
bronchiectasis. This disease is characterized by reduced maximum expiratory flow and 
slow forced emptying of the lungs (Siafakas et al., 1995). Despite being a treatable and 
preventable disease, it is still a major cause of morbidity and mortality. The prevalence 
continues to rise because of the worldwide epidemic of smoking (Nazir & Erbland, 
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2009). In this article, we demonstrated the application of the proposed method by 
conducting analysis on the data from the Genetic Epidemiology of COPD (COPDGene). 
The COPDGene Study was designed to investigate the underlying genetic factors of 
COPD, to define and characterize disease-related phenotypes, and to assess the 
association of disease-related phenotypes with the identified susceptibility genes (Regan 
et al., 2011). 
To evaluate the performance of our proposed method on a real data set, we 
applied the six methods to the COPDGene of non-Hispanic Whites population to carry 
out GWAS of COPD-related phenotypes. Similar to Liang et al., 2016, we selected 7 
quantitative COPD-related phenotypes, including % predicted FEV1 (FEV1), 
Emphysema (Emph), Emphysema Distribution (EmphDist), Gas Trapping (GasTrap), 
Airway Wall Area (Pi10), Exacerbation Frequency (ExacerFreq), Six-minute Walk 
Distance (6MWD), and 4 covariates, including BMI, Age, Pack-Years (PackYear) and 
Sex. In our analysis, EmphDist is the ratio of emphysema at -950 HU in the upper 1/3 of 
lung fields compared to the lower 1/3 of lung fields. Followed by Chu et al. (Chu et al., 
2014), we did a log transformation on EmphDist in the following analysis. We excluded 
participants with missing data in any of the 11 variables. There were total 5,430 
individuals across 630,860 SNPs used in the analyses. We first adjusted each of the 7 
phenotypes for the 4 covariates using linear models. Then, we performed the analysis 
based on the adjusted phenotypes. The detailed information can be found in Liang et al. 
(Liang et al., 2016). 
 Based on the correlation structure of the 7 COPD-related phenotypes given in 
Figure 4 in Liang et al. 2016, we changed the signs for phenotypes of FEV1 and 6MWD 
because the correlations of FEV1 and 6MWD with other 5 phenotypes are all negative. 
After changing the signs for the phenotypes of FEV1 and 6MWD, the pair-wise 
correlations among the 7 phenotypes are all positive.  
To identify SNPs associated with the 7 COPD-related phenotypes, we adopted the 
commonly used genome-wide significance level 5 × 10­ to account for multiple testing. 
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HCM divided the 7 phenotypes into 5 clusters (Figure 3.3). The first cluster contains 
three phenotypes including FEV1, Emph, and GasTrap. Each of the other four clusters 
contains only one phenotype. Table 3.4 summarized the significant SNPs identified by at 
least one method. There are 14 SNPs in Table 3.4. All of the 14 SNPs had previously 
been reported to be in association with COPD (Brehm et al., 2011; Cho et al., 2010 & 
2014; Cui et al., 2014; Du et al., 2016; Hancock et al., 2010; Li et al., 2011; Lutz et al., 
2015; Pillai et al., 2009; Wilk et al., 2009 & 2012; Young et al., 2010; Zhang et al., 2012; 
Zhu et al., 2014). From Table 3.4, we can see that HCMANOVA identifies 13 SNPs 
which are same as MANOVA; HCMultiPhen identifies 13 SNPs which are one less than 
MultiPhen; and HCTATES identifies 10 SNPs which are one more than TATES. The 
results of the real data analysis are consistent with our simulation results, that is, the 
existing methods using HCM are more powerful than or comparable with those without 
using HCM. 
 
3.4   Discussion 
In this study, we developed a HCM for joint analysis of multiple phenotypes in 
association studies. The proposed method is a dimension reduction technique by using a 
representative phenotype for each cluster of phenotypes. Applying HCM, we used 
existing methods to test the association between genetic variants and the representative 
phenotypes rather than the individual phenotypes. 
HCM has several important advantages over other dimension reduction 
techniques. First, it can produce a dendrogram of the phenotypes, which may provide 
more information on the structure of phenotypes. Second, it is computationally fast and 
easy to implement. Third, it has the distinct advantage that any valid measure of distance 
can be used in the hierarchical clustering procedure. In fact, HCM does not require 
phenotypes themselves, it only requires a dissimilarity matrix of phenotypes. This 
dissimilarity matrix of phenotypes can be estimated from the values of summary statistics 
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using independent SNPs in a GWAS (Zhu et al., 2015b). Last, any linear combination of 
the phenotypes within each cluster can represent the cluster reasonably well when the 
cluster consists of highly positively correlated phenotypes (Bühlmann et al., 2013; Shah 
& Samworth, 2013).  
We used extensive simulation studies as well as real data application to compare 
the performance of MANOVA, MultiPhen, and TATES with using HCM with that of 
without using HCM. Our simulation results showed that the three methods using HCM 
have correct type I error rates and are more powerful than or comparable with those 
without using HCM under a variety of simulation scenarios. Additionally, the real data 
analysis results demonstrated that HCM has great potential in GWAS with multiple 
phenotypes such as COPD. We also compared the proposed method with a popular 
dimension reduction method, PCA of phenotypes. Our simulation results showed that the 
three methods using HCM are more powerful than those using PCs of phenotypes. 
In this study, we use the average phenotype in each cluster as the representative 
phenotype of the cluster. We can also use the first PC of the phenotypes in each cluster as 
a representative phenotype of the cluster. However, our simulation studies (Figure A.4 
and Figure A.5) show that using the average as the representative has very similar 
performance as using the first PC as the representative. As we pointed out in the 
introduction section, any linear combination of the phenotypes within one cluster can 
represent the cluster reasonably well when the cluster consists of highly positively 
correlated phenotypes. The proposed method is more suitable for quantitative 
phenotypes. After scaling the phenotypes, the proposed method can be applied to binary 
or mixed traits. However, the performance of this approach for applying to binary or 





3.5   Tables and Figures 
Table 3.1. The estimated type I error rates of HCMANOVA. MAF is 0.3. 𝐾 is the 
number of phenotypes.	  𝛼 is the significance level. 10,000 replicates are used in the 
simulations. The type I error rates in bold indicate the values out of the bounds of the 
95% CIs. 
𝑲 𝜶 Sample Size 
Model 
1 2 3 4 
20 
0.050 
2000 0.0491 0.0479 0.0491 0.0512 
5000 0.0488 0.0507 0.0482 0.0491 
0.010 
2000 0.0092 0.0084 0.0102 0.0108 
5000 0.0113 0.0107 0.0077 0.0089 
0.001 
2000 0.0015 0.0002 0.0014 0.0009 
5000 0.0010 0.0013 0.0006 0.0009 
40 
0.050 
2000 0.0482 0.0473 0.0495 0.0505 
5000 0.0509 0.0487 0.0500 0.0509 
0.010 
2000 0.0091 0.0080 0.0098 0.0104 
5000 0.0120 0.0104 0.0100 0.0094 
0.001 
2000 0.0013 0.0005 0.0009 0.0008 





Table 3.2. The estimated type I error rates of HCMultiPhen. MAF is 0.3. 𝐾 is the number 
of phenotypes.	  𝛼 is the significance level. 10,000 replicates are used in the simulations. 
The type I error rates in bold indicate the values out of the bounds of the 95% CIs. 
𝑲 𝜶 Sample Size 
Model 
1 2 3 4 
20 
0.050 
2000 0.0519 0.0474 0.0515 0.0501 
5000 0.0482 0.0479 0.0484 0.0513 
0.010 
2000 0.0100 0.0082 0.0109 0.0104 
5000 0.0112 0.0111 0.0085 0.0100 
0.001 
2000 0.0018 0.0006 0.0011 0.0008 
5000 0.0013 0.0013 0.0008 0.0006 
40 
0.050 
2000 0.0513 0.0464 0.0512 0.0502 
5000 0.0539 0.0484 0.0496 0.0490 
0.010 
2000 0.0112 0.0078 0.0104 0.0091 
5000 0.0127 0.0111 0.0096 0.0102 
0.001 
2000 0.0013 0.0007 0.0009 0.0010 





Table 3.3. The estimated type I error rates of HCTATES. MAF is 0.3. 𝐾 is the number of 
phenotypes.	  𝛼 is the significance level. 10,000 replicates are used in the simulations. The 
type I error rates in bold indicate the values out of the bounds of the 95% CIs. 
𝑲 𝜶 Sample Size 
Model 
1 2 3 4 
20 
0.050 
2000 0.0445 0.0469 0.0509 0.0491 
5000 0.0452 0.0516 0.0498 0.0478 
0.010 
2000 0.0105 0.0088 0.0119 0.0091 
5000 0.0096 0.0102 0.0087 0.0088 
0.001 
2000 0.0016 0.0006 0.0013 0.001 
5000 0.0007 0.0012 0.0007 0.0013 
40 
0.050 
2000 0.0409 0.0464 0.0519 0.0495 
5000 0.0413 0.0486 0.0488 0.0499 
0.010 
2000 0.0088 0.0098 0.0095 0.0096 
5000 0.0097 0.011 0.0096 0.0094 
0.001 
2000 0.0008 0.0005 0.001 0.0009 





Table 3.4. Significant SNPs and the corresponding p-values in the analysis of 
COPDGene. The p-values of six tests are evaluated using asymptotic distributions. The 





Figure 3.1. Power comparisons of the six tests (HCMANOVA, MANOVA, 
HCMultiPhen, MultiPhen, HCTATES, and TATES) for the power as a function of effect 
size 𝛽 for 20 quantitative phenotypes. MAF is 0.3. The sample size is 5000. The number 
of replication is 1000. The within-factor correlation is 0.5 (𝑐? = 0.5) and the between-





Figure 3.2. Power comparisons of the six tests (HCMANOVA, MANOVA, 
HCMultiPhen, MultiPhen, HCTATES, and TATES) for the power as a function of effect 
size 𝛽 for 40 quantitative phenotypes. MAF is 0.3. The sample size is 5000. The number 
of replication is 1000. The within-factor correlation is 0.5 (𝑐? = 0.5) and the between-
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A.1   An Adaptive Fisher’s Combination Method for Joint Analysis 
of Multiple Phenotypes in Association Studies 
Without loss of generality, we assume that all phenotypes are quantitative. We use the 
linear model  to relate the  phenotype and the genotype. Let  
denote the score test statistic to test the null hypothesis . Then,  is given by 
, 
where  and . Under the null 
hypothesis, the statistic  asymptotically follows a standard normal distribution. It is 
reasonable to assume that  follows a multivariate normal distribution 
with mean 0 and covariance matrix  under the null hypothesis1. Note that 
, where  is the variance of the  phenotype. We 
have 
 
as , where  denotes the correlation coefficient between the  phenotype and 
the  phenotype. We can see that under null hypothesis, the distribution of 
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, and thus distributions of  and , are independent of 
genotypes. 
Using the same arguments as above, we can show that if  come from z 
score statistics or Wald statistics, distributions of  and  are also independent 
of the genotype (Zhu et al., 2015b). 
 
A.2   A Hierarchical Clustering Method for Dimension Reduction in 
Joint Analysis of Multiple Phenotypes 
We use PCMANOVA, PCMultiPhen, and PCTATES to represent MANOVA, 
MultiPhen, and TATES applying to the first few principal components (PCs) of 
phenotypes that explain 95% of the total variance, respectively; we use HCMANOVA-
PC1, HCMultiPhen-PC1, and HCTATES-PC1 to represent HCMANOVA, 
HCMultiPhen, and HCTATES using the first PC of the phenotypes in each cluster as a 
representative of the cluster, respectively. 
In power comparisons (Figures A.1 – A.5), we use the following set up: MAF is 
0.3; the sample size is 5000; the number of replication is 1000; and the significance level 
is 5%. In Figures A.1, A.2, A.4, and A.5, the within-factor correlation is 0.5 (𝑐? = 0.5) 
and the between-factor correlation is 0.1 (𝜌𝑐? = 0.1). 
Simulation Model S1: phenotypes 𝑦 = (𝑦(,… , 𝑦@)- are generated according to 
multivariate normal distribution 𝑀𝑉𝑁@(𝜇, Σ) with 𝜇 = 𝑥𝛽(1,… , 𝐾)- and Σ = D𝜎3 H, 




KT T T…= 1 ,, Kp p… allT
1 ,, Kp p…
1 ,, Kp p… allT
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Table A.1. The estimated type I error rates of PCMANOVA. MAF is 0.3. 𝐾 is the 
number of phenotypes.	  𝛼 is the significance level. 10,000 replicates are used in the 
simulations. The type I error rates in bold indicate the values out of the bounds of the 
95% CIs. 
𝑲 𝜶 Sample Size 
Model 
1 2 3 4 
20 
0.05 
2000 0.0499 0.0529 0.0494 0.0477 
5000 0.0493 0.0462 0.0495 0.0495 
0.01 
2000 0.0105 0.011 0.0108 0.0092 
5000 0.0098 0.0104 0.0101 0.0101 
0.001 
2000 0.0012 0.001 0.0008 0.0009 
5000 0.0008 0.001 0.0012 0.0014 
40 
0.05 
2000 0.0467 0.0521 0.0491 0.0476 
5000 0.05 0.0498 0.0492 0.0529 
0.01 
2000 0.0099 0.0112 0.0088 0.0099 
5000 0.01 0.0111 0.0097 0.011 
0.001 
2000 0.0013 0.0008 0.0011 0.0009 





Table A.2. The estimated type I error rates of PCMultiPhen. MAF is 0.3. 𝐾 is the number 
of phenotypes.	  𝛼 is the significance level. 10,000 replicates are used in the simulations. 
The type I error rates in bold indicate the values out of the bounds of the 95% CIs. 
𝑲 𝜶 Sample Size 
Model 
1 2 3 4 
20 
0.05 
2000 0.0522 0.0523 0.0507 0.0488 
5000 0.0509 0.0492 0.0507 0.0477 
0.01 
2000 0.0111 0.0114 0.0107 0.0106 
5000 0.0103 0.0104 0.0113 0.0104 
0.001 
2000 0.0013 0.0008 0.0007 0.001 
5000 0.0007 0.0009 0.0009 0.0014 
40 
0.05 
2000 0.0541 0.0566 0.0561 0.0528 
5000 0.051 0.0537 0.0504 0.0539 
0.01 
2000 0.0118 0.0112 0.0095 0.0106 
5000 0.0103 0.0115 0.0096 0.011 
0.001 
2000 0.0017 0.0009 0.0014 0.0009 





Table A.3. The estimated type I error rates of PCTATES. MAF is 0.3. 𝐾 is the number of 
phenotypes.	  𝛼 is the significance level. 10,000 replicates are used in the simulations. The 
type I error rates in bold indicate the values out of the bounds of the 95% CIs. 
𝑲 𝜶 Sample Size 
Model 
1 2 3 4 
20 
0.05 
2000 0.0476 0.0487 0.0474 0.0505 
5000 0.0472 0.053 0.047 0.0485 
0.01 
2000 0.0085 0.0103 0.0105 0.0098 
5000 0.0105 0.0094 0.0084 0.0099 
0.001 
2000 0.0005 0.0013 0.0015 0.0008 
5000 0.0011 0.0012 0.0008 0.0009 
40 
0.05 
2000 0.0524 0.0484 0.0491 0.0541 
5000 0.0503 0.0501 0.051 0.0492 
0.01 
2000 0.0088 0.0102 0.0088 0.0108 
5000 0.0128 0.0096 0.0104 0.0099 
0.001 
2000 0.0013 0.0012 0.0014 0.0016 




Figure A.1. Power comparisons of the six tests (HCMANOVA, PCMANOVA, 
HCMultiPhen, PCMultiPhen, HCTATES, and PCTATES) for the power as a function of 





Figure A.2. Power comparisons of the six tests (HCMANOVA, PCMANOVA, 
HCMultiPhen, PCMultiPhen, HCTATES, and PCTATES) for the power as a function of 




Figure A.3. Power comparisons of the six tests (HCMANOVA, MANOVA, 
HCMultiPhen, MultiPhen, HCTATES, and TATES) for the power as a function of effect 





Figure A.4. Power comparisons of the six tests (HCMANOVA, HCMANOVA-PC1, 
HCMultiPhen, HCMultiPhen-PC1, HCTATES, and HCTATES-PC1) for the power as a 




Figure A.5. Power comparisons of the six tests (HCMANOVA, HCMANOVA-PC1, 
HCMultiPhen, HCMultiPhen-PC1, HCTATES, and HCTATES-PC1) for the power as a 
function of effect size 𝛽 for 40 quantitative phenotypes.  
 
 
